Teva announces recruitment completion of Phase III clinical Study of mdc-TJK/Olanzapine LAI

Published: 10-Jan-2024
Research & Development

Teva Pharmaceutical Industries announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase III clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference

Teva announces recruitment completion of Phase III clinical Study of mdc-TJK/Olanzapine LAI

Results of the study are expected in the second half of 2024. mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the
treatment of schizophrenia.

It has the potential to be the first long-acting olanzapine with a favorable safety profile. Teva remains fully responsible to lead the development and commercialisation of olanzapine LAI globally.

MedinCell may receive up to $117m in development and commercial milestones during the coming years for mdc-TJK, and is eligible for royalties on all net sales.

  • Companies:
  • MedinCell
See more

You may also like

Distribution
Teva Pharmaceuticals, Klinge Pharma and Formycon join forces to commercialise Eylea biosimilar

Teva Pharmaceuticals, Klinge Pharma and Formycon join forces to commercialise Eylea biosimilar

Read more
FYB203, which will be marketed under the name AHZANTIVE®3 if approved by the EMA, will be commercialised by Teva Pharmaceuticals in the majority of Europe and Israel

Trending Articles

  1. Takara Bio extends biomanufacturing capabilities with custom enzyme manufacturing lab Its Gothenburg facility now has a manufacturing lab that can produce customised molecular biology products such as PCR and qPCR enzymes
  2. Grünenthal joins genetic medicine cluster CNATM to advance RNA therapeutics The pain specialist has joined the Cluster for Nucleic Acid Therapeutics Munich to strengthen its oligonucleotide drug discovery capabilities and accelerate the development of genetic medicines for neurological diseases
  3. Entact Bio appoints John G. Houston, Ph.D., to its Board of Directors A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced-proximity therapeutics
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Precision medicine and the fight to revive neuroscience R&D In discussion with Dr Kevin Robinson (KSR), Neurvati’s Dr Bruce Leuchter (BL) explores how biology-led development, better diagnosis and rare disease infrastructure could help to unlock stalled neuroscience programmes
  5. Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Distribution
Teva Pharmaceuticals, Klinge Pharma and Formycon join forces to commercialise Eylea biosimilar

Teva Pharmaceuticals, Klinge Pharma and Formycon join forces to commercialise Eylea biosimilar

FYB203, which will be marketed under the name AHZANTIVE®3 if approved by the EMA, will be commercialised by Teva Pharmaceuticals in the majority of Europe and Israel
Research & Development
Teva & Medincell release Phase III SOLARIS trial results for olanzapine in schizophrenic adults

Teva & Medincell release Phase III SOLARIS trial results for olanzapine in schizophrenic adults

The results indicate that Medincell's TEV-'749 subcutaneous extended release device for the administration of olanzapine in schizophrenic adults met primary and secondary endpoints
Research & Development
Teva UK and Closed Loop Medicine partner to advance personalised medicine development

Teva UK and Closed Loop Medicine partner to advance personalised medicine development

SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Research & Development
Sanofi and Teva's collaboration to deliver inflammatory bowel disease treatment

Sanofi and Teva's collaboration to deliver inflammatory bowel disease treatment

TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease by Sanofi and Teva Pharmaceuticals
Research & Development
Teva completes facilities purchase in Pennsylvania

Teva completes facilities purchase in Pennsylvania

Investment will see the Israeli drug-maker set up a Research & Development campus in the US
Research & Development

Teva buys rights to develop small-molecule CGRP antagonists

Enters into agreement with Heptares to develop novel products for the treatment of migraine
Regulatory

Asthma – reslizumab

Acute asthma attacks can require hospitalisation or even prove fatal, but in some sufferers the standard regimen does not give adequate control
Subscribe now